Nemaura Medical Inc. (NMRD)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nemaura Medical Inc. (NMRD) trades at $0.00 with AI Score 44/100 (Grade C). Nemaura Medical Inc. is a medical technology company focused on developing and manufacturing non-invasive continuous glucose monitoring (CGM) systems. Market cap: $4,035, Sector: Healthcare.
Price live · AI analysis from Mar 15, 2026Analyst Coverage for NMRD: NMRD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NMRD against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NMRD: the 1 perspectives are evenly split.
How is this calculated? →Nemaura Medical Inc. (NMRD) Healthcare & Pipeline Overview
Nemaura Medical Inc. develops and manufactures the sugarBEAT non-invasive continuous glucose monitoring (CGM) system, targeting individuals with Type I and Type II diabetes and pre-diabetic patients. The company's focus on non-invasive technology differentiates it in the competitive medical device market, offering a potential alternative to traditional CGM methods.
What Is the Investment Thesis for NMRD?
Nemaura Medical Inc. presents a notable research candidate within the medical device sector, driven by the increasing prevalence of diabetes and the demand for non-invasive glucose monitoring solutions. The company's sugarBEAT product offers a potential alternative to traditional CGM systems, appealing to patients seeking a more convenient and painless monitoring experience. Key value drivers include the expansion of sugarBEAT's market reach, regulatory approvals in key geographies, and the successful implementation of diabetes prevention and reversal programs. However, investors may want to evaluate the company's limited financial resources, reliance on regulatory approvals, and competition from established players in the CGM market. The company's beta of -117.34 indicates high volatility.
Based on FMP financials and quantitative analysis
NMRD Key Highlights
- Nemaura Medical Inc. focuses on non-invasive continuous glucose monitoring (CGM) technology.
- The company's primary product is sugarBEAT, a non-invasive CGM device.
- Nemaura Medical also offers proBEAT, a wellness guidance program.
- The company targets individuals with Type I and Type II diabetes, as well as pre-diabetic patients.
- Nemaura Medical Inc. was founded in 2009 and is based in New York.
Who Are NMRD's Competitors?
NMRD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ABT Abbott Laboratories | $95.28 | -0.13% | $165.95B | 70 |
| DXCM DexCom, Inc. | $72.40 | +1.61% | 28B | 93 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| PETV PetVivo Holdings, Inc. | $0.80 | -4.65% | $24.03M | 58 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NMRD's Key Strengths?
- Non-invasive CGM technology.
- Focus on diabetes prevention and reversal.
- Wellness guidance program (proBEAT).
- Established presence in the US market.
What Are NMRD's Weaknesses?
- Limited financial resources.
- Reliance on regulatory approvals.
- Competition from established players.
- Small employee count (36).
What Could Drive NMRD Stock Higher?
- Regulatory approvals for sugarBEAT in new geographic markets.
- Strategic partnerships and collaborations with pharmaceutical companies or healthcare providers.
- Clinical trials demonstrating the efficacy and safety of sugarBEAT.
- Expansion of sales and marketing efforts to increase awareness of sugarBEAT.
- Development of new products and services to expand the company's portfolio.
What Are the Key Risks for NMRD?
- Financial-distress signal — its Altman Z-Score of -23.47 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Competition from established players in the CGM market.
- Technological advancements by competitors.
- Changes in regulatory requirements.
- Limited financial resources.
- Reliance on regulatory approvals.
What Are the Growth Opportunities for NMRD?
- Expansion into new geographic markets: Nemaura Medical Inc. has the opportunity to expand its market reach by obtaining regulatory approvals for sugarBEAT in new geographic regions, such as Europe and Asia. These markets represent significant growth potential due to the large populations of individuals with diabetes and the increasing demand for CGM technology. Successful expansion into these markets could drive revenue growth and increase the company's global market share. The global CGM market is projected to reach $10 billion by 2028.
- Strategic partnerships and collaborations: Nemaura Medical Inc. can pursue strategic partnerships and collaborations with pharmaceutical companies, healthcare providers, and diabetes management organizations to expand its reach and accelerate the adoption of sugarBEAT. These partnerships could provide access to new distribution channels, patient populations, and clinical expertise. Collaborations with pharmaceutical companies could also lead to the development of integrated diabetes management solutions that combine sugarBEAT with drug therapies.
- Development of new products and services: Nemaura Medical Inc. can invest in the development of new products and services to expand its portfolio and address unmet needs in the diabetes management market. This could include developing new versions of sugarBEAT with enhanced features, such as improved accuracy, longer sensor life, and integration with mobile health apps. The company could also develop new services, such as remote patient monitoring and telehealth consultations, to provide comprehensive diabetes management support.
- Increased awareness and education: Nemaura Medical Inc. can invest in marketing and education initiatives to increase awareness of sugarBEAT and its benefits among patients and healthcare providers. This could include conducting clinical trials to demonstrate the efficacy and safety of sugarBEAT, publishing research papers in peer-reviewed journals, and participating in industry conferences and events. Increased awareness and education could drive adoption of sugarBEAT and increase the company's market share.
- Focus on pre-diabetes market: Nemaura Medical Inc. can focus on expanding its reach in the pre-diabetes market by promoting sugarBEAT as a screening tool for identifying individuals at risk of developing diabetes. The pre-diabetes market represents a significant growth opportunity due to the large number of individuals with pre-diabetes and the increasing awareness of the importance of early detection and intervention. By targeting the pre-diabetes market, Nemaura Medical Inc. can help prevent the progression of diabetes and improve the health outcomes of individuals at risk.
What Opportunities Does NMRD Have?
- Expansion into new geographic markets.
- Strategic partnerships and collaborations.
- Development of new products and services.
- Increased awareness and education.
What Threats Does NMRD Face?
- Technological advancements by competitors.
- Changes in regulatory requirements.
- Economic downturns.
- Reimbursement challenges.
What Are NMRD's Competitive Advantages?
- Proprietary non-invasive CGM technology.
- Established brand reputation in the non-invasive glucose monitoring market.
- Strong relationships with healthcare providers and diabetes management organizations.
- Intellectual property protection for sugarBEAT technology.
What Does NMRD Do?
Nemaura Medical Inc., established in 2009 and headquartered in New York, is a medical technology company specializing in the development and manufacturing of continuous glucose monitoring (CGM) systems. The company's flagship product, sugarBEAT, is a non-invasive CGM device designed for use by individuals with Type I and Type II diabetes, as well as for screening pre-diabetic patients. Unlike traditional CGM systems that require inserting a sensor under the skin, sugarBEAT utilizes a skin patch to measure glucose levels non-invasively. In addition to sugarBEAT, Nemaura Medical offers proBEAT, a wellness guidance program that provides users with personalized insights and education on factors affecting their blood sugar profiles. This program aims to empower users to make informed lifestyle choices and manage their blood sugar levels effectively. Nemaura also conducts diabetes prevention and reversal programs, further expanding its reach in the diabetes management market. The company's focus on non-invasive technology and comprehensive diabetes management solutions positions it as a player in the evolving healthcare landscape.
What Products and Services Does NMRD Offer?
- Develop and manufacture non-invasive continuous glucose monitoring (CGM) systems.
- Offer sugarBEAT, a non-invasive CGM device for individuals with diabetes and pre-diabetes.
- Provide proBEAT, a wellness guidance program for managing blood sugar levels.
- Conduct diabetes prevention and reversal programs.
- Focus on providing painless and convenient glucose monitoring solutions.
- Target individuals with Type I and Type II diabetes, as well as pre-diabetic patients.
How Does NMRD Make Money?
- Sales of sugarBEAT CGM devices and related accessories.
- Subscription fees for the proBEAT wellness guidance program.
- Revenue from diabetes prevention and reversal programs.
- Partnerships with healthcare providers and diabetes management organizations.
What Industry Does NMRD Operate In?
The medical device industry is experiencing growth, driven by technological advancements and an aging global population. The market for continuous glucose monitoring (CGM) systems is particularly expanding due to the rising prevalence of diabetes and the increasing adoption of CGM technology for diabetes management. Nemaura Medical Inc. operates in this competitive landscape, facing competition from established players like Abbott and Dexcom, as well as emerging companies developing innovative CGM solutions. The company's focus on non-invasive technology differentiates it in the market, offering a potential advantage in attracting patients seeking a more convenient and painless monitoring experience.
Who Are NMRD's Key Customers?
- Individuals with Type I diabetes.
- Individuals with Type II diabetes.
- Pre-diabetic patients.
- Healthcare providers.
- Diabetes management organizations.
FY2026 estForward Outlook
Wall Street analysts project Nemaura Medical Inc. revenue of about $3.4M for fiscal 2026, with EPS near $-0.34.
NMRD Valuation & Market Position
With a 4K market cap, Nemaura Medical Inc. sits in the micro-cap segment of the market. Relative to its peer group, NMRD's quantitative score of 44/100 is below the peer average of 76/100.
ROE 249%Key Financial Metrics
Return on equity for Nemaura Medical Inc. stands at 249.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -97.1%, showing how much profit it generates from its asset base. A current ratio of 0.61 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 1/9Financial Health
Nemaura Medical Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -23.47 places it in the distress zone, a signal of elevated financial risk.
Company Profile
Nemaura Medical Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Dewan Fazlul Hoque Chowdhury. NMRD has traded publicly since 2018.
NMRD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Nemaura's focus on non-invasive glucose monitoring is gaining traction; the market is increasingly receptive to alternatives to traditional methods.
- Recent insider activity suggests confidence in the company's long-term prospects, signaling positive internal expectations.
- Community sentiment indicates growing excitement around Nemaura's potential to disrupt the diabetes management space.
- The overall market perception of wearable health tech is bullish, which could benefit Nemaura as awareness increases.
Bear Case
- Nemaura faces stiff competition from established players in the diabetes care market; breaking through will be a challenge.
- Community sentiment reveals concerns about the company's ability to scale production to meet potential demand.
- Market perception includes skepticism about the accuracy and reliability of non-invasive glucose monitoring technology.
- Recent market developments suggest increased regulatory scrutiny in the medical device sector, potentially creating hurdles for Nemaura.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
NMRD Latest News
No recent news available for NMRD.
NMRD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NMRD.
Price Targets
Wall Street price target analysis for NMRD.
NMRD MoonshotScore
What does this score mean?
The MoonshotScore rates NMRD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
NMRD OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for quotation on OTCQX or OTCQB. Companies in this tier often face challenges in meeting minimum financial standards, disclosure requirements, or corporate governance criteria. Investing in OTC Other securities carries significant risks due to the limited information available and the potential for fraud or manipulation. These securities may also be subject to state securities laws, adding another layer of complexity for investors. Companies in this tier may be defunct or experiencing severe financial distress.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial information and disclosure.
- Low trading volume and liquidity.
- Potential for fraud or manipulation.
- Higher risk of financial distress or bankruptcy.
- Limited regulatory oversight.
- Verify the company's registration and compliance with securities laws.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the company's management team and track record.
- Understand the risks associated with investing in OTC Other securities.
- Consult with a qualified financial advisor.
- Check for any regulatory actions or legal proceedings against the company.
- Company has been in operation since 2009.
- Focus on a specific niche market (non-invasive CGM).
- Has a developed product (sugarBEAT).
- Has patents or other intellectual property protection.
Nemaura Medical Inc. Healthcare Stock: Key Questions Answered
What does Nemaura Medical Inc. do?
Nemaura Medical Inc. is a medical technology company that develops, manufactures, and markets non-invasive continuous glucose monitoring (CGM) systems. Their primary product, sugarBEAT, is a wearable skin patch that provides continuous glucose readings without the need for needles or finger pricks. This technology aims to offer a more convenient and painless way for individuals with diabetes and pre-diabetes to monitor their glucose levels. The company also offers proBEAT, a wellness guidance program designed to educate users on factors affecting blood sugar profiles and promote healthy lifestyle choices. Nemaura's focus is on providing innovative solutions for diabetes management and prevention.
What are the main risks for NMRD?
Nemaura Medical Inc. faces several risks, including competition from established players in the CGM market like Abbott and Dexcom, who have greater resources and market share. The company's reliance on regulatory approvals for sugarBEAT in various markets poses another risk, as delays or denials could significantly impact its growth prospects. Furthermore, Nemaura's limited financial resources and OTC listing increase the risk of financial distress and liquidity challenges. Investors should also consider the potential for technological advancements by competitors that could render sugarBEAT obsolete. These factors contribute to the overall risk profile of NMRD.
How does Nemaura Medical Inc. navigate regulatory approval processes?
Nemaura Medical Inc. navigates regulatory approval processes by adhering to the guidelines and requirements set forth by regulatory bodies such as the FDA in the United States and similar agencies in other countries. The company prepares comprehensive documentation, including clinical trial data, safety reports, and manufacturing information, to demonstrate the safety and efficacy of its sugarBEAT device. Nemaura also engages with regulatory agencies to address any questions or concerns and to ensure compliance with all applicable regulations. The success of Nemaura's regulatory strategy is crucial for its ability to commercialize sugarBEAT in key markets and drive revenue growth. The company's regulatory track record is currently unknown.
What is Nemaura Medical Inc.'s strategy for commercializing sugarBEAT?
Nemaura Medical Inc.'s strategy for commercializing sugarBEAT involves a multi-pronged approach, including direct sales, partnerships with healthcare providers, and distribution agreements with pharmaceutical companies and diabetes management organizations. The company focuses on targeting individuals with Type I and Type II diabetes, as well as pre-diabetic patients, through targeted marketing campaigns and educational initiatives. Nemaura also emphasizes the benefits of sugarBEAT's non-invasive technology and its potential to improve patient compliance and outcomes. The company's commercialization strategy aims to establish sugarBEAT as a leading non-invasive CGM solution in the global diabetes management market.
What are the key factors to evaluate for NMRD?
Nemaura Medical Inc. (NMRD) holds an AI score of 44/100 (low). Not financial advice.
How frequently does NMRD data refresh on this page?
NMRD prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NMRD's recent stock price performance?
Nemaura Medical Inc. (NMRD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Non-invasive CGM technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NMRD overvalued or undervalued right now?
Valuing Nemaura Medical Inc. (NMRD) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available.
- OTC stock carries higher risk.
- Analyst coverage is sparse.